

February 4, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Newspaper Advertisement-Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2025

Pursuant to Regulations 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the newspaper advertisement of the Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2025, as published in "Financial Express" and "Jansatta" on February 4, 2026.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a



VINEET LABORATORIES LIMITED
Registered Office: SY.No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana, India - 500 074. | Tel.: +91 40-24128833;
Corporate Office: H.No: 5-5-160, Malleswari Nilayam, Opp.Vishnu Theatre, Chintalkunta, L B Nagar, Hyderabad, Telangana, India - 500 074. Tel: +91 40-24128833;
Contact Person: Mr. Ramesh Kumar Bandari, Company Secretary & Compliance Officer
Email: es@vineetlabs.co.in | Website: https://vineetlabs.co.in/index.html
Corporate Identity Number: L24304TG2016PLC112888

(This is an Advertisement for information purposes only and not for publication or distribution or release outside India and is not an Offer Document)

Our Company "Vineet Laboratories Limited" ("The Company" or "VLL") (CIN: L24304TG2016PLC112888) was incorporated under the Companies Act, 2013 pursuant to a Certificate of Incorporation granted by the Registrar of Companies, Hyderabad (RoC) (presently Registrar of Companies, Telangana) at Hyderabad on November 10, 2016. Further, the API Intermediates Division of Ortin Laboratories Limited, a BSE Limited (BSE) and National Stock Exchange (NSE) Listed Company, was demerged and then merged into VLL vide Scheme of Arrangement approved by the Honourable National Company Law Tribunal, Hyderabad vide Order dated 24-12-2020. The Equity shares of the Company issued pursuant to the above stated NCLT Order were listed and traded on both BSE and NSE vide trading notice issued on June 11, 2021, respectively.

OUR PROMOTERS, SATYANARAYANA RAJU BHUPATHIRAJU, V VARAPRASADA RAO, A SRINIVASA RAJU, A RANGA RAJU, A PRABHAKAR RAJU, ALLURI MYTHILI, GADDAM VENKATA RAMANA, ALLURI ANANTHA LAXMI, GADDAM VENKATA RAMA, KANDULA MURALI MOHAN, PENMETS VENKATA KRISHNAM RAJU, P KISHORE RAJU, GADDAM SRINIVASA RAO, GADDAM BALAJI

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR "COMPANY" ONLY

ISSUE OF UP TO 99,87,258 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹30.00 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹20.00 PER RIGHTS EQUITY SHARE), FOR AN AMOUNT COLLECTIVELY NOT EXCEEDING ₹ 29,96,17,740/-* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 13 RIGHTS EQUITY SHARES FOR EVERY 12 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON DECEMBER 23, 2025 (THE "ISSUE"). FOR FURTHER DETAILS, SEE "OFFERING INFORMATION" ON PAGE 76 OF THIS LETTER OF OFFER.

*Assuming full subscription

BASIS OF ALLOTMENT

The Board of Directors of our Company thanks all Investors for their response to the Issue, which opened for subscription on January 01, 2026. Out of the total 1,429 applications for 1,06,24,801 Rights Equity Shares, 400 applications for 3,13,362 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 1,029 for 1,03,11,439 Rights Equity Shares, which was 103.25% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer and the Basis of Allotment finalized on February 2, 2026 in consultation with BSE Limited ("BSE"), the Designated Stock Exchange, and the Registrar to the Issue, the Rights Issue Committee of the Company on February 02, 2026 has approved the allotment of 99,87,258 Rights Equity Shares to the successful Applicants. In the Issue, Nil Rights Equity Shares have been kept in abeyance. All valid Applications after technical rejections have been considered for Allotment.

1. After removing technical rejections (details of which are given in the subsequent paragraphs), the total number of valid applications eligible to be considered for allotment were as detailed below:

Category	Gross			Less: Rejections/Partial Amount			Valid		
	Applications	Shares	Amount (₹)	Applications	Shares	Amount (₹)	Applications	Shares	Amount (₹)
Eligible Equity Share Holders	1,350	93,74,184	28,12,25,520.00	400	3,13,362	94,00,860	950	90,60,822	27,18,24,660.00
Renouncees	79	12,50,617	3,75,18,510.00	0	0	0	79	12,50,617	3,75,18,510.00
Total	1,429	1,06,24,801	31,87,44,030.00	400	3,13,362	94,00,860	1,029	1,03,11,439	30,93,43,170.00

2. Summary of Allotment in various categories is as under:

Category	Number of Equity Shares Allotted - against REs	Number of Equity Shares Allotted - Against valid additional shares	Total Equity Shares Allotted
Eligible Equity Shareholders	25,53,255	65,07,567	90,60,822
Renouncees	1,27,877	7,98,559	9,26,436
Total	26,81,132	73,06,126	99,87,258

Information for Allotment/refund/rejected cases: The dispatch of Allotment Advice cum Refund Intimation to the investors, as applicable, has been completed on February 02, 2026. The instructions for unblocking of funds in case of ASBA Applications were issued to SCsBs on February 02, 2026 and for refund of funds through NACH/NEFT/RTGS/direct credit were issued to Axis Bank Limited, the Banker to the Issue, on February 02, 2026. The listing application was filed with BSE and National Stock Exchange of India on February 02, 2026. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of Allotment in dematerialized form has been completed on February 03, 2026. For further details, see "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA accounts" on page 100 of the Letter of Offer. The trading in the Rights Equity Shares issued in the Rights Issue shall commence on BSE and National Stock Exchange of India upon receipt of trading permission. The trading is expected to commence on or about February 03, 2026. Further, in accordance with SEBI circular bearing reference - SEBI/HO/GFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on or about February 03, 2026.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN THE DEMATERIALISATION FORM.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that the submission of the Letter of Offer to SEBI should not in any way deemed or construed that the Letter of Offer has been cleared or approved by SEBI. The investors are advised to refer to the Letter of Offer for the full text as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of SEBI" on page 70 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of BSE as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 72 of the Letter of Offer.

"BSE Limited and National Stock Exchange of India ("the Exchange") has given vide its letters dated December 16, 2025 and December 02, 2025 respectively, permission to this Company to use the Exchange's name in this Letter of Offer as the stock exchange on which this Company's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner:

- Warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer; or
- Warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or
- Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this letter of offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever"

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.


	
Bigshare Services Private Limited S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093. Tel No: +91 22 62638200; Email: rightissue@bigshareonline.com; Website: www.bigshareonline.com Contact Person: Suraj Gupta; Investor Grievance Email: investor@bigshareonline.com; CIN: U99999MH1994PTC076534. SEBI Registration Number: INR000001385	CS Ramesh Kumar Bandari, Company Secretary & Compliance Officer Vineet Laboratories Limited Registered Office: SY.No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana, India - 500 074. Tel: +91 40-24128833;

Investors may contact the Registrar or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCsBs, giving full details such as name, address of the Applicant, contact number(s), E-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCsBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Offering Information" on page 76 of the Letter of Offer.

For Vineet Laboratories Limited
Sd/-
CS Ramesh Kumar Bandari,
Company Secretary & Compliance Officer

Place: Hyderabad
Date: February 04, 2026

Disclaimer: Our Company has filed a Letter of Offer with the Securities and Exchange Board of India and Stock Exchange. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchange where the Equity Shares are listed i.e. BSE at www.bseindia.com and the website of the company at https://vineetlabs.co.in/index.html investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.



MANKIND PHARMA LIMITED
Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4747 6600
Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4684 6700
Email: investors@mankindpharma.com, Website: www.mankindpharma.com, CIN: L74899DL1991PLC044843

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025
(₹ in Crores except as stated otherwise)

S. No.	Particulars	Consolidated					
		For the quarter ended			For the nine months ended		For the year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	3,567.20	3,697.16	3,198.79	10,834.71	9,128.07	12,207.44
2	Profit for the period/year before exceptional items and tax	615.59	624.02	488.33	1,780.10	2,000.90	2,516.33
3	Profit for the period/year after exceptional items and tax	413.88	520.18	377.87	1,378.68	1,577.60	2,006.59
4	Total comprehensive income for the period/ year	419.83	543.09	395.45	1,406.78	1,592.10	2,002.83
5	Paid up equity share capital	41.28	41.28	41.26	41.28	41.26	41.26
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.	14,291.13
7	Earnings per equity share of face value of ₹ 1 each						
	- Basic EPS (in ₹)	9.90	12.39	9.29	32.91	38.87	49.17
	- Diluted EPS (in ₹)	9.89	12.38	9.27	32.87	38.79	49.08
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	


The key standalone financial information is as under:

(₹ in Crores except as stated otherwise)

S. No.	Particulars	For the quarter ended			For the nine months ended		For the year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	2,632.68	2,636.95	2,431.15	7,839.36	7,387.95	9,507.41
2	Profit for the period/year before exceptional items and tax	588.71	525.53	512.90	1,610.41	1,865.05	2,146.50
3	Profit for the period/year after exceptional items and tax	449.47	462.27	405.45	1,329.04	1,495.22	1,780.30
4	Total comprehensive income for the period/year	452.53	478.30	414.83	1,349.21	1,564.67	1,846.63
5	Net worth (₹ Crores)	15,734.34	15,271.95	14,083.86	15,734.34	14,083.86	14,384.33
6	Debt equity ratio (times)	0.40	0.48	0.73	0.40	0.73	0.51
7	Debt service coverage ratio (times)	0.22	1.53	2.34	0.46	0.39	0.51
8	Interest service coverage ratio (times)	4.24	4.00	3.18	4.04	8.51	5.39

Notes:

- The above is an extract of the detailed format of Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.mankindpharma.com. Full Financial Results can also be accessed by scanning the QR code given hereunder.
- The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 03, 2026.
- The above unaudited Consolidated and Standalone Financial Information is for continuing operations. Refer full format of the Quarterly Financial Results for discontinued operations.



For and on behalf of
MANKIND PHARMA LIMITED
Sd/-
Sheetal Arora
Chief Executive Officer & Whole Time Director
DIN : 00704292

Place: New Delhi
Date: February 03, 2026

Bharti Life Insurance Company Limited
(Formerly known as Bharti AXA Life Insurance Company Limited)
IRDAI Registration No: 130 dated 14 July, 2006 | CIN : U66010MH2005PLC157108 | Website: www.bharti.axa.com
Registered Office: Unit No. 1902, 19th Floor, Parinee Crescenzo, 'G' Block, Bandra Kurla Complex, BKC Road, Behind MCA Ground, Bandra East, Mumbai, Maharashtra-400051
See Regulation 47 (1)(b) of the SEBI (LODR) Regulations, 2015 read with IRDAI Circular Reference IRDAI/F®/CIR/208/10/2016 dated 25th October 2016.

(Rs. in lakhs)

Sl. No.	Particulars	For the Period ended December 31, 2025	For the Period ended December 31, 2024	For the Year ended March 31, 2025
1.	Premium Income (Gross) (Refer note (c))	2,08,005	1,89,430	2,97,995
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(14,086)	(6,086)	(3,682)
3.	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items) (Refer note (d))	(14,086)	(6,086)	(3,682)
4.	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(14,086)	(6,086)	(3,682)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)] (Refer note (e))	-	-	-
6.	Equity Share Capital	4,40,379	3,92,820	3,94,320
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year (Refer note (f))	20,744	20,744	20,744
8.	Earnings Per Share (of Rs.10/- each) :-			
	1. Basic:	Rs. (0.33)	Rs. (0.16)	Rs. (0.09)
	2. Diluted:	Rs. (0.33)	Rs. (0.16)	Rs. (0.09)

Notes:

- This format is modified to reflect the terminology used in the Insurance Act and IRDAI Regulations.
- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
- Premium income is gross of reinsurance and net of Goods and service tax.
- Net Profit/(Loss) before tax, for the period would be Profit before tax as appearing in Profit and Loss Account (Shareholders' account).
- Line item no. 5 needs to be disclosed when Ind-AS becomes applicable to the Company.
- Reserves shown excluding Revaluation reserve and fair value change account.
- There are no exceptional and /or extraordinary items adjusted in the Statement of Policyholders' and Shareholders' account in accordance with AS Rules.

MAGNUS STEEL & INFRA LIMITED
(FORMERLY KNOWN AS MAGNUS RETAIL LIMITED)
CIN NO: L24319MH1978PLC416753

Regd. Off: Unit No. 365, A/Post: Shirasgaon, Tal: Niphad, Dist: Nashik - 422001
Website: www.magnussteelinfra.in ; **Email:** magnussteelinfra@gmail.com
Contact No.: +91 912271471

CORRIGENDUM TO THE NOTICE OF EXTRA-ORDINARY GENERAL MEETING

Pursuant to Section 134 of the Companies Act, 2013 ("The Act") and Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Magnus Steel and Infra Limited had sent to the Members, the notice of extra-ordinary general meeting to be held on Tuesday, February 10, 2026.

Subsequent to the issuance of the said EGM Notice, the Company hereby informs that due to an inadvertent error, the percentage of post-preferential shareholding of the proposed allottee Ms Arti Anjaria, as disclosed in the said Notice of EGM, was incorrectly stated. The percentage of post preferential shareholding of Ms Arti Anjaria is 10.33% instead of 11.11%.

All other terms, information, and contents of the Notice of EGM remain unchanged. This corrigendum shall be read in conjunction with the original Notice of EGM.


This Corrigendum is being issued to inform the shareholders regarding the modifications/amendments made in EGM Notice.

Accordingly, the Corrigendum to EGM Notice has been sent electronically to those members whose email-ids are registered with the Company.

The Corrigendum to the EGM Notice is available at the website of the company www.magnussteelinfra.in and at the website of BSE www.bseindia.com.

For Magnus Steel & Infra Limited
Sd/-
Kshipra Bansal
Company Secretary

Place : Nashik
Date : 03rd February 2026.



Mankind
Serving Life

MANKIND PHARMA LIMITED

Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; **Tel.:** +91 11 4747 6600
Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; **Tel.:** +91 11 4684 6700
Email: investors@mankindpharma.com, **Website:** www.mankindpharma.com, **CIN:** L74899DL1991PLC044843

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(₹ in Crores except as stated otherwise)

S. No.	Particulars	Consolidated					
		For the quarter ended			For the nine months ended		For the year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	3,567.20	3,697.16	3,198.79	10,834.71	9,128.07	12,207.44
2	Profit for the period/year before exceptional items and tax	615.59	624.02	488.33	1,780.10	2,000.90	2,516.33
3	Profit for the period/year after exceptional items and tax	413.88	520.18	377.87	1,378.68	1,577.60	2,006.59
4	Total comprehensive income for the period/ year	419.83	543.09	395.45	1,406.78	1,592.10	2,002.83
5	Paid up equity share capital	41.28	41.28	41.26	41.28	41.26	41.26
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.	14,291.13
7	Earnings per equity share of face value of ₹ 1 each						
	- Basic EPS (in ₹)	9.90	12.39	9.29	32.91	38.87	49.17
	- Diluted EPS (in ₹)	9.89	12.38	9.27	32.87	38.79	49.08
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	


The key standalone financial information is as under:

(₹ in Crores except as stated otherwise)

S. No.	Particulars	For the quarter ended			For the nine months ended		For the year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	2,632.68	2,636.95	2,431.15	7,839.36	7,387.95	9,507.41
2	Profit for the period/year before exceptional items and tax	588.71	525.53	512.90	1,610.41	1,865.05	2,146.50
3	Profit for the period/year after exceptional items and tax	449.47	462.27	405.45	1,329.04	1,495.22	1,780.30
4	Total comprehensive income for the period/year	452.53	478.30	414.83	1,349.21	1,564.67	1,846.63
5	Net worth (₹ Crores)	15,734.34	15,271.95	14,083.86	15,734.34	14,083.86	14,384.33
6	Debt equity ratio (times)	0.40	0.48	0.73	0.40	0.73	0.51
7	Debt service coverage ratio (times)	0.22	1.53	2.34	0.46	0.39	0.51
8	Interest service coverage ratio (times)	4.24	4.00	3.18	4.04	8.51	5.39

Notes:

- The above is an extract of the detailed format of Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.mankindpharma.com. Full Financial Results can also be accessed by scanning the QR code given hereunder.
- The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 03, 2026.
- The above unaudited Consolidated and Standalone Financial Information is for continuing operations. Refer full format of the Quarterly Financial Results for discontinued operations.



For and on behalf of
MANKIND PHARMA LIMITED
Sd/-

Sheetal Arora

Chief Executive Officer & Whole Time Director



DIN : 00704292

Place: New Delhi
Date: February 03, 2026



THE BUSINESS DAILY
FOR DAILY BUSINESS

FINANCIAL EXPRESS
SINCE 1981

(This is only an advertisement for information purposes and is not a prospectus announcement and not for distribution outside India.)																			
<div>  </div>										<div>  (Scan this code to view Prospectus) </div>									
<div> <div>KANISHK ALUMINIUM INDIA LIMITED</div> <div>Corporate Identity Number (CIN): U27109RJ2018PLC063198</div> <div> Our Company was originally incorporated as Company Limited by Shares under the name "Kanishk Aluminium Extrusions Private Limited" under the provisions of the Companies Act, 2013 and the Certificate of Incorporation was issued by Central Registration Centre, Manesar on December 05, 2018, vide certificate of incorporation bearing CIN U27109RJ2018PTC063198. Further, pursuant to Special Resolution passed by the shareholders at the Extra-Ordinary General Meeting held on August 26, 2022, the name of our Company was changed from "Kanishk Aluminium Extrusions Private Limited" to "Kanishk Aluminium India Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the Registrar of Companies, Jaipur vide dated September 21, 2022. Subsequently, our Company was converted into a Public Limited Company and consequently the name of our Company was changed from "Kanishk Aluminium India Private Limited" to "Kanishk Aluminium India Limited" vide a fresh certificate of incorporation consequent upon conversion from private company to public company dated October 30, 2024, issued by the Registrar of Companies, Central Processing Centre. Our Company's Corporate Identity Number is CIN U27109RJ2018PLC063198, please refer to chapter titled "History and Certain Other Corporate Matters" beginning on Page No. 167 of the Prospectus. </div> <div> Registered Office: Plot No. E-849 A, Fourth Phase RIICO, Boranada - 342001, Jodhpur, Rajasthan India. Website: https://kanishkindia.co.in/ E-Mail: cs@kanishkindia.co.in Telephone No: +91 92570 61994 Contact Person: Ms. Prachi Mittal, Company Secretary and Compliance Officer </div> </div>																			
<div> <div>OUR PROMOTERS: MR. PARMANAND AGARWAL, MR. ASHISH AGARWAL AND MRS. KHUSHBOO AGARWAL</div> </div>																			
<div> <div>BASIS OF ALLOTMENT</div> </div>																			
INITIAL PUBLIC OFFERING OF 40,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF KANISHK ALUMINIUM INDIA LIMITED ("KANISHK" OR "OUR COMPANY" OR "THE ISSUER") FOR CASH AT A PRICE OF ₹73/- PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 63/- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹ 2,920.00 LAKHS COMPRISING OF FRESH ISSUE OF 40,00,000 EQUITY SHARES ("THE ISSUE") OF WHICH UP TO 2,00,000 EQUITY SHARES AGGREGATING TO ₹ 146.00 LAKHS RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 38,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT AN ISSUE PRICE OF ₹ 73 PER EQUITY SHARE AGGREGATING TO ₹ 2,774.00 LAKHS ("NET ISSUE"). THE ISSUE AND THE NET ISSUE CONSTITUTE 29.76% AND 28.27% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO CHAPTER TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 283 OF HTE PROSPECTUS.																			
<div> <div>THE FACE VALUE OF THE EQUITY SHARES IS ₹10 EACH AND THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE.</div> </div>																			
<div> <div>FIXED PRICE ISSUE AT ₹ 73.00 PER EQUITY SHARE</div> <div>MINIMUM APPLICATION SIZE OF 3,200 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER</div> </div>																			
<div> <div>OFFER PROGRAMME</div> <div>OFFER OPENED ON: WEDNESDAY, JANUARY 28, 2026</div> <div>OFFER CLOSED ON: FRIDAY, JANUARY 30, 2026</div> </div>																			
<div> <div>PROPOSED LISTING: WEDNESDAY, FEBRUARY 04, 2026</div> </div>																			
The Equity Shares are proposed to be listed on the SME platform of BSE Limited i.e. BSE SME, in terms of the Chapter IX of the Securities and Exchange Board of India (Issue Capital and Disclosure Requirements) Regulations, 2018, as amended (" SEBI ICDR Regulations "). Our Company has received an in-principle approval from BSE Limited (" BSE ") for listing the Shares pursuant to letter dated September 08, 2025. The investors are advised to refer to page no. 278 of the Prospectus for the full text of the "Disclaimer Clause of the SME Platform of BSE Limited". The Designated Stock Exchange is BSE for this issue. The trading or date of listing is proposed to be commenced on Wednesday, February 04, 2026 (subject to receipt of listing and trading approvals from the BSE). The Issue is being made through the Fixed Price process and the allocation in the Net Issue to the Individuals Investors category is made pursuant to Regulation 253(2) of the SEBI ICDR Regulations, wherein a minimum of 50% of the Net Issue to the Public is initially made available for allotment to Individual Investors. The balance of Net Issue to the Public is made available for allotment to Individual Applicants other than Individual Investors and other Investors including Corporate Bodies / Institutions irrespective of number of Shares applied for. All potential investors participated in the Issue only through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details of the irrevocable bank accounts and / or UPI IDs, in case of Retail Individual Investors, if applicable, by the Self Certified Syndicate Banks (" SCSBs ").																			
<div> <div>SUBSCRIPTION DETAILS</div> </div>																			
Detail of the Applications Received																			
Category of Investor		Gross Applications			After Technical Rejections			Valid Applications											
		No. of Applications	No. of Equity Shares		No. of Applications	No. of Equity Shares		No. of Applications	No. of Equity Shares										
Market Maker		1	200,000		0	0		1	200,000										
Individual Investors		1,117	3,574,400		15	48,000		1,102											